What did Cowen do in the latest CVS analyst rating on March 13, 2026?

Cowen & Co. **reiterated a Buy** on CVS Health Corporation (CVS) on March 13, 2026. The note did not include a new price target and the stock moved **-0.87% (-$0.66)** around the update.

How should investors interpret this CVS analyst rating?

A maintained Buy means the analyst still favors the stock’s outlook. Investors should view it as confirmation of existing positive drivers rather than a signal of immediate upside. Monitor earnings and regulatory updates.

Does the Cowen note include a CVS price target?

Cowen’s public summary on March 13, 2026 did not publish a new **CVS price target**. For the full research note, see the Cowen release via StreetInsider [source](https://www.streetinsider.com/Analyst+Comments/TD+Cowen+Reiterates+Buy+Rating+on+CVS+Health+%28CVS%29/26157268.html).

How does Meyka view this CVS analyst rating?

Meyka AI treats the Cowen reiteration as supportive of consensus views. Meyka AI rates CVS with a grade of **B+**, factoring in benchmark, sector, growth, metrics, and analyst consensus.

Analyst Ratings

Cowen Maintains Buy on CVS Health (CVS) March 13, 2026

ByHuzaifa Zahoor March 16, 2026March 16, 2026

Cowen & Co. reiterated a Buy on CVS Health Corporation (CVS) on March 13, 2026, keeping its positive stance after a fresh note. The CVS analyst rating remains Buy and Cowen did not publish a new price target in the release. The note landed as the stock moved -0.87% (-$0.66) from the prior close, reflecting modest short-term selling. This update matters because Cowen is a regular, visible voice on healthcare names and its continued Buy supports the consensus view among large brokers.